Retractable Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US76129W1053
USD
0.81
-0.01 (-0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Retractable Technologies, Inc. stock-summary
stock-summary
Retractable Technologies, Inc.
Pharmaceuticals & Biotechnology
Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.
Company Coordinates stock-summary
Company Details
511 Lobo Ln , LITTLE ELM TX : 75068-5295
stock-summary
Tel: 1 972 2941010
stock-summary
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 6 Schemes (3.52%)

Foreign Institutions

Held by 6 Foreign Institutions (0.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Thomas Shaw
Chairman of the Board, President, Chief Executive Officer
Mr. John Fort
Vice President, Chief Financial Officer, Treasurer, Director
Mr. Walter Bigby
Independent Director
Mr. Darren Findley
Independent Director
Mr. Marco Laterza
Independent Director
Ms. Amy Mack
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 24 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.42

stock-summary
Return on Equity

-20.78%

stock-summary
Price to Book

0.31